SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Clinical trial NCT05436639 · COMPLETED

Trial details

NCT number: NCT05436639
Sponsor: Sparrow Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Autonomous Cortisol Secretion (ACS)ACTH-Independent Cushing Syndrome ACTH-Independent Adrenal Cushing Syndrome, Somatic

Start date: 2023-07-01
Primary completion: 2024-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.